CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Anika Therapeutics Q3 revenue rises on commercial channel growth

By Reuters News


Overview

  • Osteoarthritis solutions maker's Q3 revenue rose 10% yr/yr, driven by 17% commercial channel growth

  • Company posted adjusted net income of $3.9 mln, reversing a loss in prior-year period

  • Anika secured new 10-year Hyvisc partnership and raised lower end of 2026 revenue guidance


Outlook

  • Anika raises lower end of 2026 revenue growth guidance to 6%-10% from 5%-10%

  • Company lifts 2026 adjusted EBITDA margin outlook to 15%-17% from 13%-17%

  • Anika expects 2027 total revenue growth to be flat to 5%


Result Drivers

  • COMMERCIAL CHANNEL GROWTH - Co said 17% yr/yr growth in commercial channel drove overall revenue increase, supported by international viscosupplement and Integrity adoption

  • INTEGRITY PRODUCT EXPANSION - Integrity revenue grew more than 30% yr/yr, aided by larger implant sizes expanding use into foot & ankle and knee applications

  • OEM CHANNEL EXECUTION - Co said OEM channel revenue rose 5% yr/yr, supported by Hyvisc growth and J&J DePuy Synthes sales


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$30.59 mln

$29.44 mln (2 Analysts)

Q3 Net Loss

$311,000

Q3 Gross Profit

$18.84 mln

Q3 Income from Operations

-$712,000

Q3 Pretax Loss

$322,000


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Anika Therapeutics Inc is $23.00, about 19% above its November 5 closing price of $19.33

  • The stock recently traded at 78 times the next 12-month earnings vs. a P/E of 73 three months ago


Reuters Recommended Reads

  • Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook

  • Nov 4 - Edwards Lifesciences Q3 sales beat on TMTT portfolio adoption

  • Nov 5 - Artivion Q3 revenue beats analyst expectations driven by On-X growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.